巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Biocept

    BIOC
    1.450
    0.050
    3.57%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Biocept - 延遲價格・最後更新於 27/05 8:25
    最高位
    1.450
    最低位
    1.390
    開市價
    --
    前收市價
    1.400
    成交量(千)
    3.38
    成交額(百萬)
    0.04
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    24.54
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.970 - 1.330
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Biocept
    證券代碼
    BIOC.US
    所屬板塊
    Diagnostics & Research
    公司業務
    Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
    發行量
    16850161
    公司總部
    9955 Mesa Rim Road
    公司網址
    https://www.biocept.com
    公司電郵
    ir@biocept.com
    公司電話
    +1 858 320-8200

    美股異動 | Biocept(BIOC.US)盤前漲9% 年度營收同比增長123%

    格隆匯·
    美股異動 | Biocept(BIOC.US)盤前漲9% 年度營收同比增長123%

    美股異動 | Biocept(BIOC.US)盤前漲9% 年度營收同比增長123%

    格隆匯·
    美股異動 | Biocept(BIOC.US)盤前漲9% 年度營收同比增長123%

    關於

    Biocept(BIOC.US)所屬的行業板塊為Diagnostics & Research。
    Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
    詳細公司背景可參考: https://www.biocept.com